Page 518 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

476 MÉDICAMENTS INDUISANT OUSTABILISANTDES COUPURES DE L'ADN

HAROUSSEAU J.L., Les leucémies induites par les chimiothérapies anticancéreuses,
Bull. Cancer, 1999, 86, 929-937.
STEFANSKA B. et al., 8,11-Dihydroxy-6-[(aminoalkyl)amino]-7H-benzo [e]perimidin-7-
ones with activity in multidrug-resistant cell lines : synthesis and antitumor evaluation,
J. Med. Chem., 1999, 42, 3494-3501.
HOSSFELD D.K., Mitoxantrone-related acute myelocytic leukemias, Ann. Oncol., 2000,
11, 1215-1216.
JAIN K.K., Evaluation of mitoxantrone for the treatment of multiple sclerosis, Expert Opi-
nion lnvest. Drugs, 2000, 9, 1139-1149.
GHALIE R.G., GOODKIN D.E., Secondary leukemia after adjuvant chemotherapy for
breast cancer, J. Clin. Oncol., 2001, 19, 1231-1233.
HARVEY J. et al., Mitoxantrone and paclitaxel combination chemotherapy in metastatic
breast cancer, Cancer lnvest., 2001, 19, 225-233.
LAGE H. et al., Enhanced expression of human ABC-transporter tap is associated with
cellular resistance to mitoxantrone, FEBS Letters, 2001, 503, 179-184.
RICHÊ C., JOLIMOY G., Pharmacovigilance : les leucémies secondaires, Eurocancer,
2001, 63-64.
ROLAK L.A., Multiple sclerosis treatment 2001, Neurol. Clin., 2001, 19, 107-118.
SEITER K. et al., Secondary acute myelogenous leukemia and myelodysplasia without
abnormalities of chromosome 11q23 following treatment of acute leukemia with topoi-
somerase 11-based chemotherapy, Leukemia (Leukemia Research Fund, UK), 2001,
15, 963-970.
Novantrone® : dossier technique des Laboratoires LEDERLE.